The 92% ORR and 90% 6-month PFS data for vopimetostat + daraxonrasib in pancreatic cancer is a transformative catalyst that validates the combination approach and supports a rapid path to Phase 3. The $1.0B cash runway removes near-term financing risk through key data readouts. Traders should watch for the ESMO presentation in October and any regulatory updates on the registrational path, which could drive further upside. The widening net loss is expected for a clinical-stage biotech scaling up for late-stage development and commercialization.
Price Chart
Executive Summary
Tango Therapeutics reported Q2 2026 financial results, highlighting a net loss of $55.3M ($0.37/share) vs $38.9M ($0.35/share) in Q2 2025, with no collaboration revenue. The key catalyst is the positive Phase 1/2 data for vopimetostat + daraxonrasib in pancreatic cancer (92% ORR, 90% 6-month PFS), which the company is advancing toward a registrational path and Phase 3 trial. The cash position surged to $1.0B from $380M in Q1 2026, extending runway into 2028, while the company appointed a Chief Commercialization Officer and a new Board Chairman, signaling late-stage preparation.
Key Financial Metrics
Key Facts
- Net loss of $55.3M ($0.37/share) for Q2 2026 vs $38.9M ($0.35/share) in Q2 2025
- Cash, cash equivalents and marketable securities of $1.0 billion as of June 30, 2026, up from $379.8M at March 31, 2026
- Phase 1/2 data showed vopimetostat + daraxonrasib achieved 92% objective response rate and 90% six-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer
- Company is working with regulators and Revolution Medicines toward a registrational plan for vopimetostat plus daraxonrasib
- Fatma Ocak appointed Chief Commercialization Officer; Robert Azelby appointed Chairman of the Board
- Phase 1/2 data to be presented at 2026 ESMO Congress (Oct 23-27)
- R&D expenses increased to $37.2M from $32.8M YoY; G&A expenses doubled to $22.6M from $11.3M YoY
Financial Impact
Net loss widened by $16.4M YoY to $55.3M; cash position increased by $620M sequentially to $1.0B
Risk Factors
- Clinical trial risks in Phase 3 development
- Regulatory uncertainty around registrational path
- Execution risk in transitioning to late-stage and commercial organization
- Dependence on collaboration with Revolution Medicines
- Potential dilution from future capital raises despite current cash position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-343434 |
| Document: tngx-20260811.htm | 0001193125-26-343434 |
| Document: 0001193125-26-343434-index-headers.html | 0001193125-26-343434 |
| Document: 0001193125-26-343434-index.html | 0001193125-26-343434 |
| Document: 0001193125-26-343434.txt | 0001193125-26-343434 |
| 8-K Data (Synthetic) | 0001193125-26-343434 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $25.58 $25.20 | ▲ +1.49% | ▲ +1.04% | $23.20 (+9.28%) |
Aug 11, 2026 7w ago | 8-K | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 11, 2026 7w ago | Press Release | $26.34 $25.44 | ▼ −3.42% | ▼ −3.01% | $23.20 (−11.90%) |
Aug 9, 2026 7w ago | Institutional Cluster | $27.67 $25.29 | ▼ −8.60% | ▼ −8.55% | $23.20 (−16.14%) |
Aug 6, 2026 8w ago | 8-K | $27.07 $25.60 | ▼ −5.43% | ▼ −5.83% | $23.20 (−14.28%) |
Jun 11, 2026 16w ago | 144 | $30.94 $27.97 | ▼ −9.60% | ▼ −10.27% | $23.20 (−25.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 424B5 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
Jun 10, 2026 16w ago | 144 | $29.82 $32.29 | ▲ +8.28% | ▲ +7.85% | $23.20 (−22.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access